Vivoryon shares rebound 14% but remain 54.5% below their level from a year ago
The stock of the biotech company specializing in Alzheimer's disease reacts sharply intraday, following an earnings release that had sent the share price falling on Thursday, November 5. The rebound comes as the company's financial visibility remains short-term.
A rebound that leaves the stock below its moving averages
Vivoryon shares gain 14.24% to €0.79 in mid-afternoon trading, compared with €0.69 at the previous close. Despite this surge, the price remains below its MM20 moving average (a gap of 4.15%) and its MM200 moving average (a gap of nearly 34%).
The stock started from a low point: it has still lost 34.78% over three months and 54.49% over one year.
Today's rebound thus recovers a small part of this decline, without offsetting it. On the technical side, the RSI at 45 is neutral, and the support at €0.55 remained far from the price, as did the resistance at €1.10.
In a fairly calm market, with the CAC 40 up 0.26%, the session is mainly one of a movement specific to the stock.
A €1.7 million cash position that lasts until the second half of December
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On November 5, Vivoryon published its results for the first nine months: the net loss narrowed to €4.8 million, compared with €7.6 million a year earlier, thanks to lower expenses. Cash, meanwhile, stood at only €1.7 million as of September 30, compared with €5.6 million at the end of 2025.
According to the company, its liquidity is now sufficient to fund its operations until the second half of December 2026, and its going concern depends on new financing. It indicates that it is holding discussions with several parties regarding a partnership or financing for varoglutamstat, whose phase 2b study in diabetic nephropathy remains contingent on these funds. This December deadline is the central element of the matter: it sets the horizon for the stock over the coming weeks.
Related
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Net income: -4,8 millions d'euros
Guidance from the release
« The Company has concluded that the ability to continue as a going concern, depends on the ability to generate additional funding. » ; « its existing cash and cash equivalents will now be sufficient to fund its operating plans into the second half of December 2026 »
Risks mentioned
Company's viability beyond second half of December 2026 is dependent on ability to raise additional funds
Phase 2b DKD study initiation is subject to additional funding and partnership completion
Continued operating losses expected; business dependent on success of ongoing R&D activities
Opportunities identified
Varoglutamstat Phase 2 program has shown statistically significant kidney function improvement in two independent studies
Active negotiations with multiple parties regarding partnership or financing for varoglutamstat development
New computational analysis provides additional mechanistic support for QPCT/L inhibition in kidney disease
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
